PMVP
PMV Pharmaceuticals Inc.
$1.34
+$0.03(+2.29%)
63
Overall
--
Value
63
Tech
--
Quality
Market Cap
$63.59M
Volume
580.96K
52W Range
$0.81 - $1.84
Target Price
$5.80
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||
| Operating Expenses | $34.9M | $58.3M | $77.0M | $80.1M | $85.4M | ||
| Research & Development | $23.9M | $36.5M | $52.0M | $55.9M | $58.5M | ||
| Research Expense | $23.9M | $36.5M | $52.0M | $55.9M | $58.5M | ||
| Selling, General & Administrative | $11.0M | $21.8M | $25.1M | $24.2M | $26.9M | ||
| General & Administrative Expenses | $11.0M | $21.8M | $25.1M | $24.2M | $26.9M | ||
| Salaries & Wages | -- | -- | $10.2M | $12.4M | $8.9M | ||
| Depreciation & Amortization | $318.0K | $307.0K | $315.0K | $1.3M | $1.1M | ||
| Depreciation & Amortization | $318.0K | $307.0K | $315.0K | $1.3M | $1.1M | ||
| Other Operating Expenses | $-329.0K | $-734.0K | $-783.0K | $-736.0K | $-672.0K | ||
| OPERATING INCOME | |||||||
| Operating income | $-34.9M | $-58.3M | $-77.0M | $-80.1M | $-85.4M | ||
| EBITDA | $-34.6M | $-58.0M | $-76.6M | $-78.9M | $-84.3M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $-651.0K | $-449.0K | $-3.6M | $-11.2M | $-10.7M | ||
| Net Non-Operating Interest Income/Expense | $651.0K | $449.0K | $3.6M | $11.2M | $10.7M | ||
| Other Income/Expense | $143.0K | $-21.0K | $87.0K | $-5.4M | $-767.0K | ||
| Other Special Charges | $-143.0K | $21.0K | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-34.9M | $-58.3M | $-77.0M | $-80.1M | $-85.5M | ||
| Pre-Tax Income | $-34.4M | $-57.8M | $-73.3M | $-69.0M | $-74.8M | ||
| INCOME TAX | |||||||
| Tax Provision | $6.0K | $23.0K | $-9.0K | $2.0K | $-16.1M | ||
| NET INCOME | |||||||
| Net Income | $-34.4M | $-57.8M | $-73.3M | $-69.0M | $-58.7M | ||
| Net Income (Continuing Operations) | $-34.4M | $-57.8M | $-73.3M | $-69.0M | $-58.7M | ||
| Net Income (Discontinued Operations) | $-34.4M | $-57.8M | $-73.3M | $-69.0M | $-58.7M | ||
| Net Income (Common Stockholders) | $-34.4M | $-57.8M | $-73.3M | $-69.0M | $-58.7M | ||
| Normalized Income | -- | -- | -- | -- | $-86.3M | ||
| TOTALS | |||||||
| Total Expenses | $34.9M | $58.3M | $77.0M | $80.1M | $85.4M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $14.4M | $45.1M | $45.6M | $48.0M | $51.6M | ||
| Average Shares Outstanding (Diluted) | $14.4M | $45.1M | $45.6M | $48.0M | $51.6M | ||
| Shares Outstanding | $44.8M | $45.5M | $45.8M | $53.0M | $53.0M | ||
| Basic EPS | $-2.4 | $-1.28 | $-1.61 | $-1.44 | $-1.14 | ||
| Basic EPS (Continuing Operations) | $-2.4 | $-1.28 | $-1.61 | $-1.44 | $-1.14 | ||
| Diluted EPS | $-2.4 | $-1.28 | $-1.61 | $-1.44 | $-1.14 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-1.61 | $-1.44 | $-1.14 | ||
| OTHER METRICS | |||||||
| Gain On Sale Of P P E | -- | -- | -- | -- | $-4.6M | ||
| Other Gand A | $11.0M | $21.8M | $25.1M | $24.2M | $26.9M | ||
| Rent And Landing Fees | $561.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PMVP | $1.34 | +2.3% | 580.96K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get PMV Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW